| Literature DB >> 23665849 |
Avelino Alvarez-Ordóñez1, Francisco Javier Martínez-Lobo, Héctor Arguello, Ana Carvajal, Pedro Rubio.
Abstract
Swine Dysentery (SD) is a severe mucohaemorhagic enteric disease of pigs caused by Brachyspira hyodysenteriae, which has a large impact on pig production and causes important losses due to mortality and sub-optimal performance. Although B. hyodysenteriae has been traditionally considered a pathogen mainly transmitted by direct contact, through the introduction of subclinically infected animals into a previously uninfected herd, recent findings position B. hyodysenteriae as a potential threat for indirect transmission between farms. This article summarizes the knowledge available on the etiological agent of SD and its virulence traits, and reviews the determinants of SD transmission. The between-herds and within-herd transmission routes are addressed. The factors affecting disease transmission are thoroughly discussed, i.e., environmental survival of the pathogen, husbandry factors (production system, production stage, farm management), role of vectors, diet influence and interaction of the microorganism with gut microbiota. Finally, prophylactic and therapeutic approaches to fight against the disease are briefly described.Entities:
Mesh:
Year: 2013 PMID: 23665849 PMCID: PMC3709357 DOI: 10.3390/ijerph10051927
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Factors influencing the establishment and transmission of Swine Dysentery (SD). The determinant factor of the disease is the pathogen Brachyspira hyodisenteriae whose persistence in the environment is enhanced by low temperatures and the presence of faeces. Factors which promote the transmission, establishment and persistence of the disease are the presence of vectors, diets with high energy and proteins, and bad husbandry practices; the role of highly fermentable diets is unclear. In contrast, all-in/all-out (AI/AO) management together with cleaning and disinfection, strict biosecurity and highly digestible diets are preventive factors to the establishment of SD. Finally, the production system is a decisive factor to a great extent in the control and prevention of the disease. Farrow-to-finish herds have lower risk of SD entrance but in contrast the persistence of the pathogen is higher than in multi-site production systems.
Main antimicrobials used for the treatment and prevention of swine dysentery (SD).
| Drug | Dosage in SD treatment a | Dosage in SD prevention | Point mutations associated to decreased susceptibility b | Wild type MIC cutoff values c | Clinical MIC breakpoint d |
|---|---|---|---|---|---|
| Tiamulin | Im: 10 mg/kg bw for 1–3 days | In feed medication: 30–40 ppm | 23S rRNA gene position 2058 and 2032 | >0.25 µg/mL | >2 µg/mL |
| Po: 8 mg/kg bw for 5–7 days in drinking water | L3 ribosomal protein gene 148 | ||||
| In feed medication: 100 ppm for 7–10 days | |||||
| Valnemulin | In feed medication: 3–4 mg/kg bw for 1–4 weeks | In feed medication: 25 ppm | 23S rRNA gene position 2058 and 2032 L3 ribosomal protein gene position 149 | >0.125 µg/mL | >5 µg/mL |
| Tylosin | Im: 10 mg/kg bw for 3–5 days | - | 23S rRNA gene position 2058 | >16 µg/mL | >32 µg/mL |
| Po: 5–10 mg/kg bw in drinking water for 5–7 days | |||||
| Tylvalosin | In feed medication: 4.25 mg/kg bw for 10–14 days | In feed medication: 2.125 mg/kg·bw | 23S rRNA gene position 2058 and 2059 | >1 µg/mL | >32 µg/mL |
| Lincomycin | Po: 8 mg/kg bw in drinking water for 1 to 10 days | In feed medication: 44 ppm | 23S rRNA gene position 2058, 2059 and 2032 | >1 µg/mL | >36 µg/mL |
| In feed medication: 100 ppm until clinical signs disappear followed by 40 ppm |
kg: kilogram; mg: milligram; µg: microgram; µl: milliliter; bw: body weight; im: intramuscular; ppm: parts per million; po: per os; a Information is a summary of several commercial products. For more specific information review product labels; b This information has been obtained from [97,99,100,101]; c These cut-off values are solely to monitor any change of antibiotic resistance in the B. hyodysenteriae population [102]; d These data are used for interpreting the clinical outcome of treatment based on data of pharmacokinetic, pharmacodynamic and clinical correlations of drugs [102,103,104].